| 来源类型 | Working Paper |
| 规范类型 | 论文 |
| Antimalarial Medicine Diversion | |
| Roger Bate; Lorraine Mooney; Kimberly Hess | |
| 发表日期 | 2010-09-02 |
| 出版年 | 2010 |
| 语种 | 英语 |
| 摘要 | In October and November 2007, antimalarial medicines were collected from six cities in Africa with the intent of performing a basic quality assessment of medicines available in the private sector, following the protocol established by the Global Pharma Health Fund e.V. Minilab®, which has been adopted by branches of the United States and Nigerian Governments, amongst others. However, in preparing the resulting publication,[1] an unexpected observation was made: some public sector medicines had been diverted to private markets. That is, medicines intended to be dispensed free of charge in public health facilities, which may have been donated by countries or manufacturers as part of aid programs, or sold at heavy discounts, were bought by researchers at varying market rates in the private sector. The presence of illegally diverted medicines occurs in many markets where government health workers illegally sell “public sector drugs to retail shops”.[2] Indeed, diversion of antimalarial medicines has been seen across numerous African markets, including Nigeria, Central African Republic, Senegal, Zambia, and Tanzania.[2] Medicine diversion can lead to stock-outs in the public sector, which can have devastating effects in countries with high burdens of disease. In 2008, two years after Kenya adopted artemisinin-based combination therapy (ACT) as its first-line malaria treatment, it experienced wide stock-outs requiring intervention by the President’s Malaria Initiative (PMI).[3] In 2009, the Global Fund’s Office of the Inspector General (OIG) reported stock-outs of ACTs for adults in Tanzania.[4] Uganda has also experienced stock-outs of ACTs.[5] The successful procurement and distribution of antimalarial medicines is a matter of life and death, and in countries with perennial malaria transmission, medicines must always be available. The goal of this study was to assess the numbers of diverted antimalarial medicines from several samplings, which took place from late 2007 to early 2010 in 11 African cities, and to discuss possible causes. Read the full study as an Adobe Acrobat PDF. Roger Bate is the Legatum Fellow in Global Prosperity at AEI. Kimberly Hess is a researcher and editor at Africa Fighting Malaria. Lorraine Mooney is a researcher, editor, economist, and medical demographer at Africa Fighting Malaria. References |
| 主题 | Health Care |
| 标签 | drugs ; Health care policy ; malaria ; medicine ; Pharmaceuticals ; public ; research ; Stock market |
| URL | https://www.aei.org/research-products/working-paper/antimalarial-medicine-diversion/ |
| 来源智库 | American Enterprise Institute (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/207071 |
| 推荐引用方式 GB/T 7714 | Roger Bate,Lorraine Mooney,Kimberly Hess. Antimalarial Medicine Diversion. 2010. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| Antimalarial-drug-di（134KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
